Skip to main content
logo
Atara Biotherapeutics logo
Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
9.48
+0.25 (2.71%)
Oct 9, 2026, 4:00 PM EDT - Market closed

Atara Biotherapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
6.19120.77128.948.5763.5720.34
Revenue Growth
-96.72%-6.33%1404.02%-86.52%212.55%-
Gross Profit
4.6674.62-26.34-219.48-206.42-261.66
Operating Income
-11.1949.47-78.33-269.28-274.55-340.46
Net Income
-16.6932.69-85.4-276.13-228.3-340.14
Earnings Per Share
-1.192.57-11.41-65.19-55.96-90.78
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
9.878.4842.551.73242.82371.07
Total Debt
9.8810.3843.8357.8771.728.27
Net Cash (Debt)
-0.01-1.89-1.34-6.15171.12342.8
Net Cash Growth
-----50.08%-29.41%
Net Cash Per Share
-0.00-0.15-0.18-1.4541.9491.49

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-21.9-50.94-68.72-192.98-270.43-220.52
Capital Expenditures
---0.25-1.22-4.19-10.58
Free Cash Flow
-21.9-50.94-68.96-194.2-274.62-231.1
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
75.27%61.79%-20.43%---
Operating Margin
-180.59%40.96%-60.75%-3140.98%-431.86%-1673.85%
Pretax Margin
-268.95%27.09%-66.24%-3220.70%-359.10%-1672.05%
Profit Margin
-269.42%27.07%-66.23%-3220.88%-359.12%-1672.28%
FCF Margin
-353.49%-42.18%-53.49%-2265.25%-431.98%-1136.19%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-3.99----
Forward PE
31.8719.660.30---
PS Ratio
15.361.080.606.104.8968.51